Higher antibiotic doses may be necessary to reach target drug concentrations.[32] Early studies focusing on inflammatory factor-targeted treatments for sepsis, such as interleukin-1 receptor antagonists and tumor necrosis factor antibodies, have demonstrated significant therapeutic benefits in clinical settings.[33] The HDL mimetic CER-001 has shown promise in alleviating various sepsis symptoms and potentially protecting organ function. The gene discussed is TNF; the disease is Sepsis.